Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin in Cardiomyopathy
NCT06846086Phase 3
Key facts
- Status
- Recruiting
- Start
- Feb 2025
- Primary completion
- Jan 2026
- Countries
- 1
- Sponsor
- Tanta University
- Modality
- Small Molecules
- Drugs
- melatonin
- Conditions
- cardiomyopathy
01
Overview
Phase 3, randomised, double-blind trial of melatonin in cardiomyopathy (2 arms), sponsored by Tanta University. Primary endpoints: Blood Pressure Measurement at 3 months, Heart Rate (HR) Measurement at 3 months and 2 more. Started Feb 2025; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Interventional group
Melatonin 10 mg once daily + Standard of Care
Control group
Placebo + Standard of Care
03
Who it enrols
Adult patients with confirmed cardiomyopathy, stable on standard medications, excluding those with severe kidney/liver impairment, recent hospitalization, or significant arrhythmias.
04
Endpoints
Primary
Blood Pressure Measurement
Heart Rate (HR) Measurement
Echocardiographic Parameters
Serum Concentration of NT Pro- BNP
Secondary
composite clinical endpoint score
Biochemical Markers
Beyond the preview
Go deeper on NCT06846086.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846086.